Surrozen, Inc.
- SRZN
- NASDAQ
- Biotechnology
- Wnt Pathway Modulators
- Tissue Repair Therapeutics
$23.84
Today +1.71%Quote Oct 19, 2026, 08:00 PM UTC
+44.05%over the last month
Max drawdown −30.4%From 1-month high −29.2%3 months +3.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
44
Founded
2015
Market value
$280.2M
Quote Oct 19
Analyst target
$54.00
+126.5% from here
Floor
$22.94
3.8% below price
Resistance
$24.94
4.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SRZNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free